Breaking Finance News

A report released today by Vetr Inc. about Clovis Oncology Inc (NASDAQ:CLVS) bumps the target price to $39.27

Having a price of $37.38, Clovis Oncology Inc (NASDAQ:CLVS) traded 1.60% higher on the day. With the last stock price up 64.74% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.03% over the same period. CLVS has recorded a 50-day average of $32.24 and a two hundred day average of $22.69. Trade Volume was down over the average, with 0 shares of CLVS changing hands under the typical 3,155,780

In a report released on 11/28/2016 Vetr Inc. raised the target price of Clovis Oncology Inc (NASDAQ:CLVS) to $39.27 reporting a potential upside of 0.05%.

On Tuesday November 22, 2016, Vetr Inc. released a statement about Clovis Oncology Inc (NASDAQ:CLVS) upped the target price from $0.00 to $33.59 that suggested a downside of -0.03%.

Performance Chart

Clovis Oncology Inc (NASDAQ:CLVS)

With a total market value of $0, Clovis Oncology Inc has with a one year low of $11.57 and a 52 week high of $40.29 .

In addition to Vetr Inc. reporting its stock price target, a total of 8 brokers have issued a research note on the company. The average stock price target is $17.50 with two analysts rating the company a strong buy, zero brokerages rating the stock a buy, 6 brokerages rating the stock a hold, zero equity analysts rating the company a underperform, and lastly zero equity analysts rating the stock a sell.

General Information About Clovis Oncology Inc (NASDAQ:CLVS)

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.